PT-141 (Bremelanotide) Research Guide: Mechanism, Studies & Reconstitution Protocol

PT-141, formally known as bremelanotide, is a synthetic cyclic heptapeptide melanocortin receptor agonist structurally derived from Melanotan II (MT-II). Originally investigated as a sunless tanning agent and later repositioned for sexual dysfunction research, bremelanotide became the first centrally acting pharmacological agent approved by the FDA for hypoactive sexual desire disorder (HSDD) in premenopausal women (Vyleesi, 2019). Its unique mechanism — acting on the central nervous system rather than the vascular system — distinguishes it from PDE5 inhibitors and has made it a significant tool compound in neurosexology and melanocortin receptor research.

For research use only. Not intended for human or veterinary use.

Background: From MT-II to Bremelanotide

Bremelanotide evolved from clinical observations made during early human studies of Melanotan II. Wessells et al. (1998) noted that MT-II produced unexpected spontaneous penile erections in male volunteers enrolled in a tanning study — a side effect that redirected research interest toward the melanocortin system’s role in sexual function. Subsequent medicinal chemistry work at Palatin Technologies produced bremelanotide through modification of MT-II’s C-terminal amide to a C-terminal hydroxyl group, which eliminated MT-II’s blood pressure-elevating effects (attributed to MC1R-mediated vascular tone changes) while retaining MC3R and MC4R agonism relevant to sexual function.

The resulting compound — PT-141/bremelanotide — is selective for MC3R and MC4R relative to MC1R, greatly reducing the pigmentary side effects that characterize MT-II and making it more suitable for chronic or repeated research administration.

Structure and Pharmacology

Bremelanotide is a cyclic heptapeptide with the sequence cyclo-(Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OH), derived from the core active sequence of α-MSH. Key pharmacological properties:

• Molecular weight: 1025.2 Da
• Receptor profile: MC3R and MC4R agonist (primary); reduced MC1R activity vs. MT-II
• Half-life: Approximately 2.7 hours (subcutaneous administration)
• Bioavailability: High via subcutaneous route; limited oral bioavailability
• Mechanism: Central (CNS) — does not require vascular response; acts on hypothalamic and limbic circuits

Mechanism of Action

MC4R and Central Sexual Arousal Pathways

The primary mechanism underlying bremelanotide’s effects on sexual function involves MC4R activation in the hypothalamus — specifically in the paraventricular nucleus (PVN) and medial preoptic area (MPOA), regions critical for the regulation of sexual motivation and arousal in both male and female animal models. MC4R neurons in these areas project to spinal cord circuits (including the lumbosacral autonomic nuclei) and brainstem regions involved in genital reflexes and dopaminergic reward pathways.

Unlike sildenafil and other PDE5 inhibitors — which act peripherally by augmenting nitric oxide-mediated vasodilation — bremelanotide acts upstream in the central nervous system on the neural circuits that generate sexual desire and arousal, independent of vascular function. This CNS mechanism is the basis for its utility in desire disorders (HSDD) rather than purely erectile or arousal dysfunction.

Dopaminergic Interaction

Preclinical research suggests bremelanotide’s pro-sexual effects involve interaction with the mesolimbic dopamine system. MC4R activation in the MPOA has been shown to increase dopamine release in the nucleus accumbens, a key node in reward and motivation circuitry. This interaction with dopaminergic reward pathways is consistent with melanocortin signaling promoting motivational salience for sexual stimuli rather than simply facilitating peripheral genital response.

MC3R and Appetite Modulation

Bremelanotide’s MC3R agonism contributes to the nausea observed in a subset of research subjects and clinical trial participants — MC3R is involved in vagal afferent signaling associated with visceral sensation. This remains a focus of ongoing optimization in melanocortin research, driving efforts to develop MC4R-selective agonists with reduced MC3R activity.

Key Research Findings

Male Sexual Dysfunction

Molinoff et al. (2003) published Phase II clinical data demonstrating that intranasal bremelanotide significantly improved erectile function scores in men with mild-to-moderate erectile dysfunction compared to placebo, including in a subset of men who had not responded to sildenafil. The central mechanism of action was proposed as the basis for this complementary efficacy, with MC4R activation recruiting CNS arousal pathways independently of the nitric oxide/cGMP pathway targeted by PDE5 inhibitors.

Female Sexual Dysfunction (HSDD)

The RECONNECT trials — two pivotal Phase III randomized controlled studies — evaluated subcutaneous bremelanotide in premenopausal women with HSDD. Clayton et al. (2016) and subsequent RECONNECT publications reported statistically significant improvements in the Female Sexual Function Index (FSFI) desire domain and reductions in distress associated with low sexual desire compared to placebo. These trials formed the basis for FDA approval of Vyleesi (bremelanotide injection) in June 2019 — the first centrally acting pharmacological treatment approved for HSDD.

Animal Model Research

Bremelanotide has been extensively used in rodent and non-human primate models to dissect the neural circuits of sexual motivation. Pfaus et al. (2004) demonstrated that systemic bremelanotide in female rats increased solicitation behavior, pacing, and receptivity in ways consistent with enhanced sexual motivation rather than simply facilitated peripheral arousal. Intracranial microinjection studies have refined the specific hypothalamic nuclei responsible for these effects. These animal model findings have been instrumental in characterizing the distinct neural contributions of desire vs. arousal vs. orgasm in the sexual response cycle.

Cardioprotective Research

Independent of its sexual function research applications, bremelanotide has been studied for cardioprotective effects in ischemia-reperfusion injury models. Several preclinical studies have demonstrated that melanocortin receptor activation — including via bremelanotide — reduces infarct size and preserves cardiac function in rodent myocardial ischemia models, an effect attributed to MC3R/MC4R-mediated suppression of inflammatory signaling and apoptotic pathways in cardiac tissue.

PT-141 vs. Melanotan II: Research Comparison

For research specifically targeting MC4R-mediated sexual function pathways without confounding pigmentary or blood pressure effects, bremelanotide is the preferred tool compound. MT-II remains useful when broad-spectrum melanocortin agonism — including MC1R — is relevant to the experimental design. See our Melanotan II Research Guide for a detailed companion overview.

Reconstitution Protocol

PT-141/Bremelanotide is supplied as a lyophilized powder and must be reconstituted with bacteriostatic water prior to research use.

• Inject bacteriostatic water slowly along the inner wall of the vial — do not direct stream onto the powder
• Gently swirl until fully dissolved; the solution should be clear and colorless
• Common research concentration: 10 mg/mL (add 1 mL BAC water to a 10 mg vial)
• Refrigerate reconstituted solution at 2–8°C; use within 4 weeks; protect from light
• Do not freeze reconstituted solution

References

• Wessells, H., Fuciarelli, K., Hansen, J., Hadley, M. E., Hruby, V. J., Dorr, R., & Levine, N. (1998). Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction. Journal of Urology, 160(2), 389–393.
• Molinoff, P. B., Shadiack, A. M., Earle, D., Diamond, L. E., & Quon, C. Y. (2003). PT-141: A melanocortin agonist for the treatment of sexual dysfunction. Annals of the New York Academy of Sciences, 994, 96–102.
• Clayton, A. H., Althof, S. E., Kingsberg, S., DeRogatis, L. R., Kroll, R., Goldstein, I., … & Portman, D. J. (2016). Bremelanotide for female sexual dysfunctions in premenopausal women: A randomized, placebo-controlled dose-finding trial. Women’s Health, 12(3), 325–337.
• Pfaus, J. G., Shadiack, A., Van Soest, T., Tse, M., & Molinoff, P. (2004). Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Proceedings of the National Academy of Sciences, 101(27), 10201–10204.
• Cone, R. D. (2006). Studies on the physiological functions of the melanocortin system. Endocrine Reviews, 27(7), 736–749.

All content on this site is intended strictly for in vitro research and laboratory use. Products sold by Exceed Enhancement are not approved by the FDA and are not intended for human consumption, therapeutic use, or veterinary application.